Concordantly, NAMPT inhibitors, such as FK866, have been tested as a novel cancer therapy and showed reduced tumor burden in preclinical studies, leading to several clinical trials (NCT00432107, NCT00431912) [17]. Here, NAMPT is linked to cancer.